Effectiveness of Subcutaneous Casirivimab and Imdevimab in Ambulatory Patients with COVID-19

INTRODUCTION: Data on real-world effectiveness of subcutaneous (SC) casirivimab and imdevimab (CAS+IMD) for the treatment of coronavirus disease 2019 (COVID-19) are limited. The objective of this study was to assess the effectiveness of SC CAS+IMD versus no antibody treatment among patients with COV...

Descripción completa

Detalles Bibliográficos
Autores principales: Jalbert, Jessica J., Hussein, Mohamed, Mastey, Vera, Sanchez, Robert J., Wang, Degang, Murdock, Dana, Fariñas, Laura, Bussey, Jonathan, Duart, Carlos, Hirshberg, Boaz, Weinreich, David M., Wei, Wenhui
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2022
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9526200/
https://www.ncbi.nlm.nih.gov/pubmed/36181639
http://dx.doi.org/10.1007/s40121-022-00691-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9526200/
https://www.ncbi.nlm.nih.gov/pubmed/36181639
http://dx.doi.org/10.1007/s40121-022-00691-z

Ejemplares similares